Effect of Theophylline on Ischemically Induced Hippocampal Damage in Mongolian Gerbils: A Behavioral and Histopathological Study

Journal of Cerebral Blood Flow and Metabolism - Tập 7 Số 1 - Trang 74-81 - 1987
Karl Asmund Rudolphi1, Manfred Keil2, H. J. Hinze1
1Pharma Research, Hoechst AG, Werk Albert, Wiesbaden
2* Department of Experimental Pathology, Hoechst AG, Frankfurt/M, F.R.G.

Tóm tắt

We investigated the influence of the adenosine antagonist theophylline on the degree of hippocampal cell damage in the Mongolian gerbil following brief periods of forebrain ischemia. Male gerbils were randomly divided into nine groups. Ten minutes before surgery, four groups, which were later subjected to 1, 2, 3, or 5 min of bilateral carotid occlusion under halothane anesthesia, received theophylline (30 mg/kg, p.o.). Four groups served as nontreated ischemic controls; the ninth group was used to measure theophylline serum concentration. Neurological symptoms were classified by using a behavioral score. Fourteen days after ischemia, the brains were removed, and the hippocampus was histologically examined “blind” for the degree of cell damage in the CA1 sector, which was expressed as a semiquantitative histopathological score. There were no behavioral or histological abnormalities in either the control or theophylline group with 1 min of ischemia. With increasing duration of ischemia, the neurological symptoms worsened and the number of necrotic pyramidal cells increased significantly. The pretreatment with theophylline only moderately aggravated the neurological symptoms, whereas it enhanced the ischemic cell damage significantly. The results are discussed with respect to recent findings that theophylline may block putatively protective effects of endogenous adenosine, whose concentration in the brain is known to rise significantly during ischemia.

Từ khóa


Tài liệu tham khảo

Brierley JB, 1976, Greenfield's Neuropathology, 3, 41

Brown AW, 1968, Br J Exp Pathol, 49, 87

10.1007/BF00687191

10.1016/0304-3940(83)90127-1

10.1016/0165-6147(86)90285-3

10.1152/ajplegacy.1943.138.3.421

10.1111/j.1476-5381.1980.tb10883.x

10.1001/archneur.1975.00490500089013

Gottstein U, 1974, Internist, 15, 575

10.1161/01.STR.3.5.560

Gottstein U, 1961, Med Klin, 56, 1598

Grome JJ, 1986, Naunyn Schmiedeberg Arch Pharmacol, 461, 1

Hadorn W, 1960, Schweiz Med Wochenschr, 90, 1301

10.1007/BF00688952

Herrschaft H, 1979, Therapiewoche, 27, 4525

Hossmann KA, 1973, Z Neurol, 204, 281

10.1161/01.STR.7.3.301

Imdahl A, 1985, J Cereb Blood Flow Metabol, 5, S409

10.1007/BF00696570

10.1161/01.STR.11.2.203

10.1016/0006-8993(82)90833-2

10.1007/BF00691853

10.1007/BF00691854

10.1007/BF00695577

Kogure K, 1975, Arch Neurol, 32, 352, 10.1001/archneur.1975.00490430043005

de Nó Lorente, 1934, J Psychol Neurol, 46, 113

10.1161/01.STR.9.5.477

Morii S, 1983, J Cereb Blood Flow Metabol, 3, S480

10.1111/j.1600-0404.1982.tb04528.x

10.1016/S0378-4347(00)80510-1

10.1007/BF02661184

10.1111/j.1600-0404.1980.tb05428.x

Rail TW, 1985, The Pharmacological Basis of Therapeutics, 7, 589

Sachs L, 1968, Angewandte Statistik

10.1016/0006-8993(79)90910-7

10.1016/0006-8993(86)90204-0

10.1002/ana.410070202

10.1038/jcbfm.1981.18

10.1038/jcbfm.1984.52

10.1126/science.6093256

10.1111/j.1600-0404.1970.tb05612.x

10.1007/BF00691869

10.1126/science.209541

10.1161/01.RES.45.4.486

Winn HR, 1981, Am J Physiol, 241, 235

Winn HR, 1985, Adenosine: Receptors and Modulation of Cell Function, 379

10.1152/physrev.1936.16.4.545